Log in

NASDAQ:CRVSCorvus Pharmaceuticals Stock Price, Forecast & News

$3.30
-0.15 (-4.35 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.01
Now: $3.30
$3.56
50-Day Range
$2.15
MA: $3.03
$4.05
52-Week Range
$1.01
Now: $3.30
$8.10
Volume176,636 shs
Average Volume192,209 shs
Market Capitalization$92.24 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Read More
Corvus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.42 per share

Profitability

Net Income$-46,670,000.00

Miscellaneous

Employees49
Market Cap$92.24 million
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

How has Corvus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRVS stock has increased by 21.8% and is now trading at $3.30. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Corvus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corvus Pharmaceuticals.

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Corvus Pharmaceuticals.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) released its quarterly earnings data on Thursday, April, 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.04. View Corvus Pharmaceuticals' earnings history.

What price target have analysts set for CRVS?

3 brokers have issued 12-month target prices for Corvus Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Corvus Pharmaceuticals' share price to reach $8.33 in the next twelve months. This suggests a possible upside of 152.5% from the stock's current price. View analysts' price targets for Corvus Pharmaceuticals.

Has Corvus Pharmaceuticals been receiving favorable news coverage?

News headlines about CRVS stock have trended very positive this week, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corvus Pharmaceuticals earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCorvus Pharmaceuticals.

Who are some of Corvus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD), ImmunoGen (IMGN) and Immunomedics (IMMU).

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:
  • Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
  • Mr. Leiv Lea, Chief Financial Officer (Age 65)
  • Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
  • Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
  • Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Two Sigma Investments LP (0.36%), Connor Clark & Lunn Investment Management Ltd. (0.31%), Hikari Power Ltd (0.22%), Morgan Stanley (0.12%), Russell Investments Group Ltd. (0.11%) and Two Sigma Advisers LP (0.10%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View institutional ownership trends for Corvus Pharmaceuticals.

Which institutional investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Two Sigma Investments LP, and Morgan Stanley. View insider buying and selling activity for Corvus Pharmaceuticals.

Which institutional investors are buying Corvus Pharmaceuticals stock?

CRVS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, Two Sigma Advisers LP, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller. View insider buying and selling activity for Corvus Pharmaceuticals.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $3.30.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $92.24 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Corvus Pharmaceuticals employs 49 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.